A balanced ECS approach may involve inhibiting CB1 to reduce hyperphagia, lipogenesis, and insulin resistance while activating CB2 to encourage anti-inflammatory responses and lipid breakdown (Tables 1 and 2). This evidence concerns the gene CNR1 and Insulin resistance.